Find investors
← Back to all investors
CL
ResearchedAngel Investors

Carl Labanz

Venture Analyst

Angel InvestorsSeed Round
Pitch Carl

Get their honest, personalized take on your startup.

Sign in to pitch Carl

At a glance

Full Name
Carl Labanz
Title
Venture Analyst (2019–2023), later Manager of Process Innovation, at CincyTech — now Solutions Architect at Zapier
Firm
CincyTech (CincyTech USA)
Firm Type
Seed-stage venture capital / venture development firm (commonly listed among Cincinnati angel & VC investors)
Investment Stage
Pre-seed and seed (through Series A)
Check Size
CincyTech typically writes $500K–$1.5M seed checks; Labanz's aggregated investing profile lists a $100K–$5M range with a ~$1.5M sweet spot
Target Company Profile
Early-stage founders with novel, defensible technology addressing urgent problems — frequently spun out of regional university and hospital research
Sector Focus
Human/digital health and life sciences, deep tech, enterprise & productivity software, security, accessibility, and sustainability
Geographic Focus
Southwest Ohio and the broader Midwest
Location
Cincinnati, Ohio

Background

Carl Labanz spent his venture career at CincyTech, one of the Midwest's most active seed funds, which invests in disruptive human-health and technology companies rooted in the Ohio innovation ecosystem. He joined as a Venture Analyst in 2019 and held that role through 2023, supporting deal sourcing, diligence, and portfolio work across the firm's health and technology practices. In 2023 he transitioned to Manager of Process Innovation at CincyTech, focusing on internal operations and workflow improvement rather than pure investing.

Before venture capital, Labanz worked at the Daniel Morgan Graduate School of National Security in Washington, D.C., an independent graduate school of national security and intelligence, where he served as board treasurer and director of finance and helped a small team advance the school toward accreditation candidacy. This finance-and-operations background carried into his analyst and process-innovation work at CincyTech.

He holds bachelor's degrees in History and International Studies from Xavier University and an MBA from the University of Cincinnati's Carl H. Lindner College of Business. He also earned a 2021 certificate from Rouxbe Online Culinary School and has served as a director and treasurer of the Cincy Soccer League. As of 2026, his LinkedIn lists his current role as Solutions Architect at Zapier, indicating he has moved from venture investing into a technology solutions role — so treat the CincyTech contact details as potentially dated.

Investment Thesis & Focus

  • Invests at the earliest stages — pre-seed and seed — where CincyTech partners early to "transform ideas into world-class companies," often before a product is commercialized.
  • Backs founders with novel and defensible technology aimed at urgent problems in health and tech; CincyTech's portfolio skews heavily toward digital/human health, life sciences, and deep tech.
  • Comfortable with capital-intensive science: CincyTech-led rounds have funded preclinical research and clinical trials (e.g., vaccines, therapeutics), not just software.
  • Seed checks generally in the $500K–$1.5M range, with the firm frequently leading or co-leading and syndicating alongside regional and national investors.
  • Strong bias toward the Ohio / Southwest Ohio ecosystem, translating university and hospital research (Cincinnati Children's, University of Cincinnati) into scalable companies.

Notable Investments

  • Blue Water Vaccines — universal flu vaccine developer; CincyTech led a $7M round in 2019 to fund preclinical work and a planned Phase 1 trial.
  • Losant — enterprise IoT application platform; closed a $5.2M Series A (2018) with CincyTech backing.
  • Myonexus Therapeutics — gene therapy company acquired by Sarepta Therapeutics in 2019 (CincyTech portfolio).
  • Amify — Amazon marketplace growth platform; CincyTech portfolio company, acquired by Cart.com in 2024.
  • Airway Therapeutics / Aerpio / Akebia Therapeutics — life-sciences companies in CincyTech's therapeutics portfolio.

Unlock the full research

Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.

One-time. Stays unlocked for you.